Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration

A Multi-Center, Open-Label, Single Ascending Dose Study To Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal CLG561 in Subjects With Advanced Age-Related Macular Degeneration

The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).

Study Overview

• Status: Completed
• Conditions: Age-related Macular Degeneration
• Intervention / Treatment: Drug: CLG561

Detailed Description

Subjects were divided into 5 cohorts, with the subjects in each cohort being administered a single IVT dose of CLG561 in 1 of 5 concentration levels A-E, where A=lowest and E=highest. All subjects received active CLG561. Progress from one cohort to the next was time-lagged to allow for safety review. Dosing was also time-lagged within each cohort. Only one eye (designated as the study eye) was dosed per subject. Post-dose safety assessments and ocular examination occurred immediately after the IVT injection and continued throughout the outpatient visits at pre-determined timepoints. Collection of post-injection blood samples began after the IVT injection at pre-determined timepoints. Subjects were followed for up to 84 days.

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of age-related macular degeneration in study eye, as specified in protocol.
• Poor visual acuity in study eye, as specified in protocol.
• Willing to receive meningitis and pneumonia vaccinations at least 2 weeks prior to study treatment.
• Females must be post-menopausal and/or surgically sterile.
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Treatments to the study eye within 28 days prior to study treatment, as specified in protocol.
• Any disease or medication expected to cause systemic or ocular immunosuppression.
• Participation in another interventional clinical study or use of any experimental treatment for AMD within 12 weeks prior to study treatment.
• Other protocol-defined exclusion criteria may apply.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CLG561, Concentration Level A; Single 50 μL intravitreal injection of CLG561, Dose Level A	Drug: CLG561; Administered by intravitreal injection, Day 1
Experimental: CLG561, Concentration Level B; Single 50 μL intravitreal injection of CLG561, Dose Level B	Drug: CLG561; Administered by intravitreal injection, Day 1
Experimental: CLG561, Concentration Level C; Single 50 μL intravitreal injection of CLG561, Dose Level C	Drug: CLG561; Administered by intravitreal injection, Day 1
Experimental: CLG561, Concentration Level D; Single 50 μL intravitreal injection of CLG561, Dose Level D	Drug: CLG561; Administered by intravitreal injection, Day 1
Experimental: CLG561, Concentration Level E; Single 100 μL intravitreal injection of CLG561, Dose Level E	Drug: CLG561; Administered by intravitreal injection, Day 1

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) by Visit - Study Eye	BCVA (with spectacles or other visual corrective devices) using Early Treatment Diabetic Retinopathy Study (ETDRS) testing was reported in letters read correctly. Improvement of BCVA was defined as an increase (gain) in letters read from the baseline assessment. One eye (study eye) contributed to the analysis.	Baseline, Day 2, Day 4, Day 15, Day 29, Day 57, Day 85
Mean Intra-Ocular Pressure (IOP) by Visit - Study Eye	IOP was measured by Goldmann applanation tonometry or tonopen, at the discretion of the Investigator, and reported in mmHg (millimeters of mercury). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) contributed to the analysis.	Baseline, Day 1, Day 2, Day 4, Day 15, Day 29, Day 57, Day 85
Number of Subjects With Change From Normal to Abnormal in Fundus Examination at Any Post-Therapy Visit as Compared to Baseline Assessment	A dilated fundus examination was performed to evaluate the health of the retina, macula, choroid, and optic nerve. Subjects having a normal baseline evaluation were examined at subsequent visits, and any change from normal to abnormal was recorded. Criteria for reclassifying from normal to abnormal were left to the opinion of the investigators. One eye (study eye) contributed to the analysis. None of the abnormalities were deemed related to the study medication.	Baseline, Day 2, Day 4, Day 8, Day 15, Day 29, Day 57, Day 85
Number of Subjects With a Change From Normal to Abnormal in Ocular Signs at Any Post-Therapy Visit as Compared to Baseline Assessment	A slit-lamp biomicroscopy examination was performed to evaluate the anterior segment of the eye. Subjects having a normal baseline evaluation were examined at subsequent visits, and any change from normal to abnormal was recorded. Criteria for reclassifying from normal to abnormal were left to the opinion of the investigators. One eye (study eye) contributed to the analysis. None of the abnormalities were deemed related to the study medication.	Baseline, Day 2, Day 4, Day 8, Day 15, Day 29, Day 57, Day 85

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area Under the Serum Concentration-time Curve (AUC) From Time Zero to All [AUC(0-all)]	Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental pharmacokinetic (PK) method.	Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85
Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-last)]	Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.	Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85
Time to Reach the Maximum Serum Concentration After Drug Administration (Tmax)	Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.	Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85
Dose Normalized Observed Maximum Serum Concentration Following Drug Administration (Cmax/D)	Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.	Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85
Dose-normalized Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-last)/D]	Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.	Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85
Area Under the Serum Concentration-time Curve From Time Zero to Time "t" Where t is a Defined Time Point After Administration [AUC(0-t)]	Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.	Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85
Terminal Elimination Half-life (T½)	Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.	Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85
The Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F)	Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.	Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85
Apparent Systemic (or Total Body) Clearance From Serum Following Extravascular Administration (CL/F)	Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.	Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85

Collaborators and Investigators

• Sponsor: Alcon Research
• Investigators: Study Director: Head of Clinical Sciences, CA CSI NS/Opth, Alcon Research

Study record dates

Study Major Dates

• Study Start: May 1, 2013
• Primary Completion (Actual): November 1, 2014
• Study Completion (Actual): November 1, 2014

Study Registration Dates

• First Submitted: April 16, 2013
• First Submitted That Met QC Criteria: April 17, 2013
• First Posted (Estimate): April 18, 2013

Study Record Updates

• Last Update Posted (Estimate): March 25, 2016
• Last Update Submitted That Met QC Criteria: February 24, 2016
• Last Verified: February 1, 2016

More Information

Terms related to this study

• Keywords: Safety; AMD; Tolerability; Age-related macular degeneration; Choroidal neovascularization; Geographic Atrophy; First in human; Serum PK; Intravitreal (IVT)
• Additional Relevant MeSH Terms: Eye Diseases; Retinal Degeneration; Retinal Diseases; Macular Degeneration
• Other Study ID Numbers: C-12-074